1 |
Paez JG, Janne PA, Lee JC, et al (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-1500.
DOI
ScienceOn
|
2 |
Pao W, Miller VA, Politi KA, et al (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2, e73.
DOI
ScienceOn
|
3 |
Ramachandran PV, Ignacimuthu S (2012). RNA Interference as a Plausible Anticancer Therapeutic Tool. Asian Pac J Cancer P, 13, 2445-52.
과학기술학회마을
DOI
ScienceOn
|
4 |
Sekido Y (2010). Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci, 101, 1-6.
DOI
ScienceOn
|
5 |
Sequist LV, Martins RG, Spigel D, et al (2008). First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol, 26, 2442-9.
DOI
ScienceOn
|
6 |
Suda K, Murakami I, Katayama T, et al (2010). Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res, 16, 5489-98.
DOI
ScienceOn
|
7 |
Xu N, Shen C, Luo Y, et al (2012). Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun, 425, 468-72.
DOI
ScienceOn
|
8 |
Yang F, Miao L, Mei Y, et al (2013). Retinoic acid-induced HOXA5 expression is co-regulated by HuR and miR-130a. Cell Signal, 25, 1476-85.
DOI
ScienceOn
|
9 |
Yang L, Li N, Wang H, et al (2012). Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep, 28, 592-600.
|
10 |
Kosaka T, Yatabe Y, Endoh H, et al (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res, 12, 5764-9.
DOI
ScienceOn
|
11 |
Gazdar AF (2009). Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene, 28 Suppl 1, S24-31.
DOI
ScienceOn
|
12 |
Guo A, Villen J, Kornhauser J, et al (2008). Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A, 105, 692-7.
DOI
ScienceOn
|
13 |
Kong YW, Ferland-McCollough D, Jackson TJ, et al (2012). microRNAs in cancer management. Lancet Oncol, 13, e249-58.
DOI
ScienceOn
|
14 |
Li H, Schmid-Bindert G, Wang D, et al (2011). Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Adv Med Sci, 56, 275-84.
DOI
ScienceOn
|
15 |
Luo W, Huang B, Li Z, et al (2013). MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS One, 8, e64759.
DOI
|
16 |
Matoulkova E, Michalova E, Vojtesek B, et al (2012). The role of the 3' untranslated region in post-transcriptional regulation of protein expression in mammalian cells. RNA Biol, 9, 563-76.
DOI
ScienceOn
|
17 |
Molina JR, Yang P, Cassivi SD, et al (2008). Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 83, 584-94.
DOI
|
18 |
Mujahid S, Nielsen HC, Volpe MV (2013). MiR-221 and miR-130a regulate lung airway and vascular development. PLoS One, 8, e55911.
DOI
|
19 |
Acunzo M, Visone R, Romano G, et al (2012). miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene, 31, 634-42.
|
20 |
Oxnard GR, Miller VA (2010). Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology (Williston Park), 24, 392-9.
|
21 |
Belalcazar A, Azana D, Perez CA, et al (2012). Targeting the Met pathway in lung cancer. Expert Rev Anticancer Ther, 12, 519-28.
DOI
ScienceOn
|
22 |
Boll K, Reiche K, Kasack K, et al (2013). MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene, 32, 277-85.
DOI
ScienceOn
|
23 |
Burris HA, 3rd (2009). Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene, 28 Suppl 1, S4-13.
DOI
ScienceOn
|
24 |
Dimitroulis J, Stathopoulos GP (2005). Evolution of non-small cell lung cancer chemotherapy (Review). Oncol Rep, 13, 923-30.
|
25 |
Engelman JA, Zejnullahu K, Mitsudomi T, et al (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316, 1039-43.
DOI
ScienceOn
|
26 |
Farazi TA, Spitzer JI, Morozov P, et al (2011). miRNAs in human cancer. J Pathol, 223, 102-15.
DOI
ScienceOn
|
27 |
Garofalo M, Romano G, Di Leva G, et al (2012). EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med, 18, 74-82.
|
28 |
Chen Y, Gorski DH (2008). Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood, 111, 1217-26.
|
29 |
Zhang W, Mendoza MC, Pei X, et al (2012). Down-regulation of CMTM8 induces epithelial-to-mesenchymal transition-like changes via c-MET/extracellular signal-regulated kinase (ERK) signaling. J Biol Chem, 287, 11850-8.
DOI
ScienceOn
|
30 |
Sandberg R, Neilson JR, Sarma A, et al (2008). Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites. Science, 320, 1643-7.
DOI
ScienceOn
|